Sequel Med Tech, LLC and Senseonics announce availability of twiist Automated Insulin Delivery System to treat Type 1 Diabetes

Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc., a medical technology company focused on long-term, implantable Continuous Glucose Monitoring (CGM) systems for people with diabetes,  announced full availability of the twiist Automated Insulin Delivery (AID) System integrated with the Eversense® 365 CGM system across the U.S.

Powered by Tidepool, twiist is the first AID system compatible with Eversense 365, the world’s only one-year CGM. This powerful combination is a significant leap forward for the diabetes community, offering a transformative solution for long-term diabetes management by significantly reducing the burden of frequent sensor changes and re-pairing while maintaining exceptional CGM accuracy.

“As the first AID system to integrate with a year‑long CGM, twiist expands the options available to people with diabetes,” said Joanna Mitri, M.D., M.S., Chief Medical Officer at Sequel. “People deserve choice and technology that fits the realities of their lives. Our goal is to provide a system that supports the many different ways individuals and care teams approach diabetes every day.”

In combining the precision of the twiist insulin delivery system with the unmatched longevity of Eversense 365, Sequel and Senseonics are enhancing diabetes management by offering more tools to manage diabetes care, supporting glucose control, increased convenience, and greater flexibility.

“Diabetes doesn’t take days off, so the technology I use can’t either,” said Paris Hicks, a person living with type 1 diabetes. “Using twiist with Eversense 365 means fewer disruptions, more confidence, and a system that actually works for the way I live. I really appreciate how easy managing my diabetes has been with this combination.”

“National availability of Eversense 365 with twiist marks an important next phase of our journey,” said Brian Hansen, Chief Commercial Officer of Senseonics. “It adds to the growing momentum behind Eversense 365, which is designed to provide reliable glucose data over longer periods of time in order to reduce the daily burden people with diabetes often face. By pairing this groundbreaking CGM with an advanced insulin delivery system, users can spend less time managing devices and more time focusing on their lives.”

Sequel is committed to offering people with type 1 diabetes greater flexibility and choice in managing their diabetes. Those who use twiist can personalize their diabetes management by choosing between two compatible CGM partners: Senseonics’ Eversense 365 or Abbott’s FreeStyle Libre 3 Plus sensor, depending on their personal preferences and needs.

Integration with Eversense 365 is an important milestone as it is the only long-term CGM system available, offering 365 days of uninterrupted, reliable glucose readings. It is the most accurate CGM in low glucose ranges where errors can have the greatest impact on patient safety and treatment decisions.

The combination is now being used in real-world care settings and is broadly available for people with type 1 diabetes in the U.S.